The Anti-IL-13 Reference Antibody (GSK 679586) is utilized in research and development for chronic allergic conditions, such as moderate to severe asthma, particularly in models with elevated type 2 inflammation. It specifically targets and inhibits interleukin-13 (IL-13), a key cytokine driving airway inflammation, hyperresponsiveness, mucus production, and swelling. This reference antibody serves as a benchmark for evaluating the efficacy of novel anti-IL-13 antibodies and biosimilars. It is also employed in laboratory disease models to elucidate immune mechanisms in asthma and other inflammatory disorders like atopic dermatitis and chronic rhinosinusitis with nasal polyps. Not intended for direct clinical administration, it supports preclinical studies mimicking biologic therapies for patients unresponsive to standard inhaled treatments.